Mobile

An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured with Recombinant Human Albumin (rHA) when a...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-002438-12

An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured with Recombinant Human Albumin (rHA) when administered to Children in their Second Year of Life

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To describe the safety profile of a second dose of ProQuad® manufactured with rHA when administered to children in their second year of life

Critère d'inclusion

  • Combined Measles, Mumps, Rubella and Varicella Live Vaccine

Liens